World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
44337
World Ranking
12924
National Ranking
6605

Overview

Shaker R. Dakhil is affiliated with the University of Kansas in the United States and has a research focus in the fields of Medicine and Biochemistry, Genetics, and Molecular Biology. Their work is particularly concentrated in oncology and pulmonary medicine.

Their primary subfields of study include:

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research
  • Radiology, Nuclear Medicine and Imaging
  • Genetics

The main topics covered in their research span:

  • Advanced Breast Cancer Therapies
  • Cancer Immunotherapy and Biomarkers
  • Breast Cancer Treatment Studies
  • Monoclonal and Polyclonal Antibodies Research
  • Cancer Genomics and Diagnostics
  • Lung Cancer Treatments and Mutations
  • Estrogen and related hormone effects

Notable recent papers authored or co-authored by Shaker R. Dakhil include:

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study, 2020, The Lancet Oncology
  • Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial, 2020, The Lancet Oncology
  • Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451, 2021, Journal of Clinical Oncology
  • First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations, 2022, Journal of Thoracic Oncology
  • Fatigue, anxiety, and quality of life in breast cancer patients compared to non-cancer controls: a nationwide longitudinal analysis, 2021, Breast Cancer Research and Treatment

Frequently publishing in key scientific journals, this researcher has contributed extensively to:

  • Journal of Clinical Oncology
  • Cancer Research
  • The Oncologist
  • The Lancet Oncology
  • Breast Cancer Research and Treatment

Collaboration is a significant aspect of their work, with frequent co-authors including:

  • Charles L. Wiseman
  • Jarrod P. Holmes
  • Sandra M. Swain
  • Adam Brufsky
  • Louis Fehrenbacher

Best Publications

  • Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

    Edward H. Romond;Edith A. Perez;John Bryant;Vera J. Suman

  • Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27

    Priya Rastogi;Stewart J. Anderson;Harry D. Bear;Charles E. Geyer

  • Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

    Luis Paz-Ares;Mikhail Dvorkin;Yuanbin Chen;Niels Reinmuth

  • Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

    Thomas M. Habermann;Edie A. Weller;Vicki A. Morrison;Randy D. Gascoyne

  • Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

    Edward B. Garon;Tudor Eliade Ciuleanu;Oscar Arrieta;Kumar Prabhash

  • Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial

    Charles L Loprinzi;John W Kugler;Jeff A Sloan;James A Mailliard

  • Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study

    Evanthia Galanis;Jan C. Buckner;Matthew J. Maurer;Jeffrey I. Kreisberg

  • Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial

    Toni K. Choueiri;Susan Halabi;Ben L. Sanford;Olwen Hahn

  • Cardiac Safety Analysis of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab in the North Central Cancer Treatment Group N9831 Adjuvant Breast Cancer Trial

    Edith A. Perez;Vera J. Suman;Nancy E. Davidson;George W. Sledge

  • Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

    Sandra M Swain;Sandra M Swain;David Miles;Sung-Bae Kim;Young-Hyuck Im

  • Oxaliplatin, Fluorouracil, and Leucovorin for Patients With Unresectable Liver-Only Metastases From Colorectal Cancer: A North Central Cancer Treatment Group Phase II Study

    Steven R. Alberts;William L. Horvath;William C. Sternfeld;Richard M. Goldberg

  • Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321

    Bart Barlogie;Robert A. Kyle;Kenneth C. Anderson;Philip R. Greipp

  • Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy.

    Halle C F Moore;Joseph M. Unger;Kelly Anne Phillips;Frances Boyle;Frances Boyle

  • Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma

    Thomas E. Witzig;Susan M. Geyer;Irene Ghobrial;David J. Inwards

  • Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

    Thomas J. Lynch;Taral Patel;Luke Dreisbach;Michael McCleod

  • Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124

    Primo N. Lara;Ronald Natale;John Crowley;Heinz Josef Lenz

  • Phase III Study of Immediate Compared With Delayed Docetaxel After Front-Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer

    Panos M. Fidias;Shaker R. Dakhil;Alan P. Lyss;David M. Loesch

  • Dronabinol Versus Megestrol Acetate Versus Combination Therapy for Cancer-Associated Anorexia: A North Central Cancer Treatment Group Study

    Aminah Jatoi;Harold E. Windschitl;Charles L. Loprinzi;Jeff A. Sloan

  • Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Kazuhiko Nakagawa;Edward B Garon;Takashi Seto;Makoto Nishio

  • Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

    Sung-Bae Kim;Rebecca Dent;Seock-Ah Im;Marc Espié

Frequent Co-Authors

Jeff A. Sloan
Jeff A. Sloan Mayo Clinic
Paul J. Novotny
Paul J. Novotny Mayo Clinic
Gary R. Morrow
Gary R. Morrow University of Rochester Medical Center
Gabriel N. Hortobagyi
Gabriel N. Hortobagyi The University of Texas MD Anderson Cancer Center
William E. Barlow
William E. Barlow Fred Hutchinson Cancer Research Center
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
Julie R. Gralow
Julie R. Gralow American Society of Clinical Oncology
Kathy S. Albain
Kathy S. Albain Loyola University Chicago

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Embarking on a career in medicine doesn't always require the traditional path through medical school. Many students explore alternative healthcare careers for a faster and more flexible entry into the workforce. For example, financial aid for medical billing and coding can help cover the cost of training, making this in-demand profession accessible to more people.

Nursing remains one of the most popular and impactful career options. Opportunities now exist to enroll in a nursing school that does not require teas test, removing a major barrier for many prospective students.

For those interested in management roles, an healthcare administration accelerated degree offers a streamlined track to leadership positions within hospitals, clinics, or health organizations.

Registered nurses looking to advance their careers can consider adn to fnp programs, which bridge their credentials towards becoming a Family Nurse Practitioner in less time, often through online study.

These alternative pathways allow students greater flexibility, specialized focus, and the ability to enter the healthcare field more quickly, all while taking advantage of online learning options and financial support.

Best Scientists Citing Shaker R. Dakhil

Trending Scientists